Clinical Trial Detail

NCT ID NCT02751528
Title QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors NantBioScience, Inc.
Indications

Her2-receptor positive breast cancer

Therapies

ETBX-021

Age Groups: senior adult

Additional content available in CKB BOOST